Meanwhile, chemerin inhibits LDL uptake by reducing LDLR and SORT1 in trophoblasts, which leads to an increase in the release of lipids and the lipid-related protein (triglycerides, cholesterol, phospholipids, and chemerin) from the placenta to the maternal circulation, as well as a lower LDL uptake from the circulation to the placenta, eventually resulting in dyslipidemia in the patient (Fig. 6). Here, RARRES2 is linked to metabolic syndrome.